Ovarian function in young patients (pts) treated with postneoadjuvant palbociclib (PAL) and endocrine therapy (ET) for hormone receptor (HR)-positive, HER2-negative early breast cancer (BC): Explorative analysis in Penelope-B

Furlanetto J, Marme F, Thode C, Nekljudova V, Liu Y, Jimenez MM, Reimer T, Knudsen E, Denkert C, Bassy M, Martin LA, Karn T, Sinn BV, Filipitis M, Van Mackelenbergh M, Fasching P, Mueller V, Stickeler E, Schem C, Loibl S (2022)

Publication Type: Conference contribution

Publication year: 2022

Journal

Publisher: ELSEVIER

City/Town: AMSTERDAM

Pages Range: S149-S150

Conference Proceedings Title: ANNALS OF ONCOLOGY

DOI: 10.1016/j.annonc.2022.03.076

Authors with CRIS profile

Involved external institutions

GBG Forschungs GmbH (German Breast Group) Germany (DE) Ruprecht-Karls-Universität Heidelberg Germany (DE) amedes Medizinische Dienstleistungen GmbH Germany (DE) Pfizer, Inc. United States (USA) (US) Universität Rostock Germany (DE) Roswell Park Cancer Institute United States (USA) (US) Philipps-Universität Marburg Germany (DE) The Institute of Cancer Research (ICR) United Kingdom (GB) Goethe-Universität Frankfurt am Main Germany (DE) Hospital General Universitario Gregorio Marañón Spain (ES) Charité - Universitätsmedizin Berlin Germany (DE) Medizinische Universität Wien Austria (AT) Universitätsklinikum Schleswig-Holstein (UKSH) Germany (DE) Universitätsklinikum Hamburg-Eppendorf (UKE) Germany (DE) Universitätsklinikum Aachen (UKA) Germany (DE) Krankenhaus Jerusalem Germany (DE) Centrum für Hämatologie und Onkologie Bethanien Germany (DE)

How to cite

APA:

Furlanetto, J., Marme, F., Thode, C., Nekljudova, V., Liu, Y., Jimenez, M.M.,... Loibl, S. (2022). Ovarian function in young patients (pts) treated with postneoadjuvant palbociclib (PAL) and endocrine therapy (ET) for hormone receptor (HR)-positive, HER2-negative early breast cancer (BC): Explorative analysis in Penelope-B. In ANNALS OF ONCOLOGY (pp. S149-S150). AMSTERDAM: ELSEVIER.

MLA:

Furlanetto, J., et al. "Ovarian function in young patients (pts) treated with postneoadjuvant palbociclib (PAL) and endocrine therapy (ET) for hormone receptor (HR)-positive, HER2-negative early breast cancer (BC): Explorative analysis in Penelope-B." Proceedings of the ANNALS OF ONCOLOGY AMSTERDAM: ELSEVIER, 2022. S149-S150.

BibTeX: Download